Hoxworth Blood Center welcomes new chief financial officer/executive doctor of business administration
Hoxworth Blood Center, University of Cincinnati, is pleased to announce the appointment of new chief financial officer/executive doctor of business administration (CFO/EDBA), Nick Leibold, MBA.
Leibold comes to Hoxworth after a financial career in highly prestigious investment, financial and pharmaceutical corporations in New York and work as a successful chief financial officer and co-chief executive officer of a pharmaceutical company with employees and operations across 40+ states.
“Mr. Leibold’s expertise will help us support and strengthen the services we provide to patients and donors in the Tri-State,” states Hoxworth director, José Cancelas, MD, PhD. “He brings many attributes to the senior leadership of Hoxworth and will play a key role in our strategic efforts going forward.”
Leibold, a Cincinnati native, earned his B.S. in Finance from Miami University and his MBA from the Stern School of Business of New York University.
Hoxworth Blood Center welcomed Leibold’s arrival on March 27, 2023.
Related Stories
Recent advances may speed time to endometriosis diagnosis
March 16, 2026
The average time to clinical diagnosis of endometriosis is nine years. Definitive diagnosis of the disease is difficult, and until recently, has relied on laparoscopic surgery. Now, as Medscape recently reported, novel clinical recommendations, advanced diagnostic tools and research into inflammation and immune responses, are bringing promise that women with endometriosis will find relief sooner and without surgery, according to experts, including Katie Burns, PhD, University of Cincinnati College of Medicine associate professor.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.